表紙
市場調查報告書
商品編碼
1024226

自體免疫疾病:現在及今後的市場機會,流行病學調查,市場動態,開發平台分析,r-NPV分析

Autoimmune Diseases - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 373 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供自體免疫疾病的相關調查,提供流行病學研究,市場規模和預測,活用KOL洞察的新加入企業價格策略,風險調整淨現值(RNPV)分析,開發管線洞察和基準概述,競爭情形,未滿足需求和機會等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病的概要與流行病學調查

第4章 自體免疫疾病的市場銷售額:現在·預測(2020-2030)

第5章 開發平台(管線)的洞察和基準預測

第6章 自體免疫疾病競爭空間的交易活動

第7章 自體免疫疾病管線藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH913

GervanoRA's pipeline analysis and opportunity assessment report "Autoimmune Diseases - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Autoimmune Diseases pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Autoimmune Diseases drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Autoimmune Diseases area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Autoimmune Diseases drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Autoimmune Diseases historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Autoimmune Diseases Market (2020) and the Forecasted Autoimmune Diseases Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Autoimmune Diseases Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Autoimmune Diseases Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Autoimmune Diseases Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: AUTOIMMUNE DISEASES CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF AUTOIMMUNE DISEASES COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF AUTOIMMUNE DISEASES PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: TOP 5 AUTOIMMUNE DISEASE DEALS WITH RESPECT TO DEAL AMOUNT (2019-2020)
  • TABLE 03: LIST OF AUTOIMMUNE DISEASES WITH AFFECTED ORGANS
  • TABLE 04 LIST OF DIFFERENT IN-VITRO DIAGNOSTIC TESTS USED TO DIAGNOSE AUTOIMMUNE DISEASES
  • TABLE 05: LATEST DRUG APPROVALS FOR AUTOIMMUNE DISEASES FROM FDA AND EMA
  • TABLE 06: MAJOR MERGERS AND ACQUISITION DEALS IN AUTOIMMUNE DISEASE AREA
  • TABLE 07: MAJOR COLLABORATION DEALS IN AUTOIMMUNE DISEASE AREA
  • TABLE 08: MAJOR LICENSING DEALS IN AUTOIMMUNE DISEASE AREA
  • TABLE 09: MAJOR FINANCING DEALS IN AUTOIMMUNE DISEASE AREA
  • TABLE 10: MAJOR TERMINATION DEALS IN AUTOIMMUNE DISEASE AREA
  • TABLE 11: RA PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 12: RHEUMATOID ARTHRITIS DRUG CANDIDATES UNDER PRE-REGISTRATION
  • TABLE 13: RHEUMATOID ARTHRITIS PHASE 3 DRUG CANDIDATES
  • TABLE 14: RHEUMATOID ARTHRITIS PHASE 2 DRUG CANDIDATES
  • TABLE 15: RHEUMATOID ARTHRITIS PHASE 1 DRUG CANDIDATES
  • TABLE 16: RHEUMATOID ARTHRITIS PRECLINICAL DRUG CANDIDATES
  • TABLE 17: RHEUMATOID ARTHRITIS PRECLINICAL DRUG CANDIDATES
  • TABLE 18: RHEUMATOID ARTHRITIS INACTIVE AND DISCONTINUED PIPELINE DRUG CANDIDATES
  • TABLE 19: CLINICAL STAGE RHEUMATOID ARTHRITIS PIPELINE DRUGS WITH INJECTABLE AS ROA
  • TABLE 20: CLINICAL STAGE RHEUMATOID ARTHRITIS PIPELINE DRUGS WITH ORAL ROA
  • TABLE 21: CLINICAL STAGE RHEUMATOID ARTHRITIS PIPELINE DRUGS ANALYSIS BY MAJOR DRUG CLASSES
  • TABLE 22: RA PIPELINE DRUGS ANALYTICS BY COMPANY TYPE
  • TABLE 23: T1D PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 24: REGISTRATION STAGE PIPELINE MOLECULES OF T1D
  • TABLE 25: PHASE 3 PIPELINE MOLECULES OF T1D
  • TABLE 26: PHASE 2 PIPELINE MOLECULES OF T1D
  • TABLE 27: PHASE 1 PIPELINE MOLECULES OF T1D
  • TABLE 28: PRECLINICAL PIPELINE MOLECULES OF T1D
  • TABLE 29: EARLY R&D PIPELINE MOLECULES OF T1D
  • TABLE 30: T1D INACTIVE AND DISCONTINUED PIPELINE MOLECULES

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE COMPETITIVE SPACE
  • FIGURE 02: BASIC MECHANISM OF AUTOIMMUNITY
  • FIGURE 03: AUTOIMMUNE DISEASE DEALS SCENARIO
  • FIGURE 04: AUTOIMMUNE DISEASE DEALS ANALYTICS BY ANNUAL FREQUENCY
  • FIGURE 05: AUTOIMMUNE DISEASES DEALS SCENARIO IN 2020
  • FIGURE 06: RHEUMATOID ARTHRITIS PIPELINE VS STAGES OF DEVELOPMENT
  • FIGURE 07: RHEUMATOID ARTHRITIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 08: RHEUMATOID ARTHRITIS DRUG PIPELINE ANALYTICS BY ROA
  • FIGURE 09: RA DRUG PIPELINE ANALYTICS BY MOLECULE TYPE
  • FIGURE 10: GEOGRAPHICAL CATEGORIZATION OF CLINICAL STAGE COMPANIES WORKING ON RA
  • FIGURE 11: T1D PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • FIGURE 12: T1D PIPELINE DRUG ANALYTICS BY GEOGRAPHY
  • FIGURE 13: T1D PIPELINE DRUG ANALYTICS BY ROUTE OF ADMINISTRATION
  • FIGURE 14: T1D PIPELINE DRUG ANALYTICS BY MOLECULE TYPE
  • FIGURE 15: GEOGRAPHY VS CLINICAL STAGE COMPANIES WORKING ON T1D
  • FIGURE 16: CROHN'S DISEASE PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
  • FIGURE 17: CROHN'S DISEASE PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 18: CROHN'S DISEASE PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 19: CROHN'S DISEASE PIPELINE ANALYSIS BY MOLECULE TYPE
  • FIGURE 20: CROHN'S DISEASE PIPELINE ANALYSIS BY COMPANY TYPE
  • FIGURE 21: AUTOIMMUNE HEPATITIS PIPELINE DRUGS BY STAGES OF DEVELOPMENT
  • FIGURE 22: AIH DRUG PIPELINE ANALYTICS BY MOLECULE TYPE
  • FIGURE 23: GEOGRAPHICAL CATEGORIZATION OF COMPANIES WORKING ON AIH
  • FIGURE 24: PIPELINE MOLECULES OF AUTOIMMUNE DISEASES AFFECTING SENSORY ORGANS
  • FIGURE 25: PIPELINE MOLECULES OF AUTOIMMUNE DISEASES AFFECTING NERVOUS SYSTEM
  • FIGURE 26: PIPELINE MOLECULES OF MAJOR AUTOIMMUNE DISEASES AFFECTING MUSCULOSKELETAL SYSTEM
  • FIGURE 27: PIPELINE MOLECULES OF MAJOR AUTOIMMUNE DISEASES AFFECTING BLOOD/HEART AND CIRCULATORY SYSTEM
  • FIGURE 28: PIPELINE MOLECULES OF MAJOR AUTOIMMUNE DISEASES AFFECTING URINARY SYSTEM
  • FIGURE 29: PIPELINE MOLECULES OF MAJOR AUTOIMMUNE DISEASES AFFECTING GASTROINTESTINAL SYSTEM
  • FIGURE 30: PIPELINE MOLECULES OF MAJOR AUTOIMMUNE DISEASES AFFECTING MULTIPLE TISSUES AND ORGANS